Business Description
Annovis Bio Inc
NAICS : 325411
SIC : 2833
ISIN : US03615A1088
Share Class Description:
FRA:07X: Ordinary SharesDescription
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.76 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -79.1 | |||||
| 3-Year EPS without NRI Growth Rate | -78.4 | |||||
| 3-Year FCF Growth Rate | -91.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.82 | |||||
| 9-Day RSI | 37.74 | |||||
| 14-Day RSI | 44.06 | |||||
| 6-1 Month Momentum % | 15.5 | |||||
| 12-1 Month Momentum % | -39.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | |||||
| Quick Ratio | 2.39 | |||||
| Cash Ratio | 1.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -412.6 | |||||
| ROA % | -268.11 | |||||
| ROIC % | -2030.66 | |||||
| ROC (Joel Greenblatt) % | -2030.66 | |||||
| ROCE % | -275.32 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.07 | |||||
| EV-to-Forward-EBIT | -2.92 | |||||
| EV-to-EBITDA | -2.07 | |||||
| EV-to-Forward-EBITDA | -2.49 | |||||
| EV-to-FCF | -2.33 | |||||
| Earnings Yield (Greenblatt) % | -48.31 | |||||
| FCF Yield % | -40.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Annovis Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.763 | ||
| Beta | 2.29 | ||
| Volatility % | 164.82 | ||
| 14-Day RSI | 44.06 | ||
| 14-Day ATR (€) | 0.472665 | ||
| 20-Day SMA (€) | 10.454 | ||
| 12-1 Month Momentum % | -39.94 | ||
| 52-Week Range (€) | 5.11 - 18.1 | ||
| Shares Outstanding (Mil) | 11.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Annovis Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Annovis Bio Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Annovis Bio Inc Frequently Asked Questions
What is Annovis Bio Inc(FRA:07X)'s stock price today?
The current price of FRA:07X is €9.37. The 52 week high of FRA:07X is €18.10 and 52 week low is €5.11.
When is next earnings date of Annovis Bio Inc(FRA:07X)?
The next earnings date of Annovis Bio Inc(FRA:07X) is 2024-05-10 Est..
Does Annovis Bio Inc(FRA:07X) pay dividends? If so, how much?
Annovis Bio Inc(FRA:07X) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers